En Banc Rehearing Denied Over OxyContin Potency

A federal appeals court has denied a request for a panel or en banc rehearing of a qui tam suit alleging Purdue Pharma LP overstated the potency of its successful painkiller...

Already a subscriber? Click here to view full article